Perspective Therapeutics
CATXCATX · Stock Price
Historical price data
Overview
Perspective Therapeutics is a clinical-stage biotech on a mission to transform cancer treatment with its innovative targeted alpha-particle therapy (TAT) platform. Formed in 2023 via a strategic merger, the company leverages a proprietary Pb-212-based approach to deliver high-energy, short-range radiation directly to cancer cells, minimizing damage to healthy tissue. Its strategy focuses on advancing a pipeline of image-guided theranostics for neuroendocrine tumors, melanoma, and other solid tumors, positioning it at the forefront of the next wave in radiopharmaceuticals.
Technology Platform
A proprietary Pb-212-based targeted alpha-particle therapy (TAT) platform featuring chemically matched theranostic isotope pairs (Pb-203 for imaging, Pb-212 for therapy) conjugated to tumor-specific peptides via a proprietary lead-specific chelator.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| [203Pb]VMT-α-NET + [212Pb]VMT-α-NET | Neuroendocrine Tumors Unresectable | Phase 1/2 | |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Recurrent Melanoma (Skin) | Phase 1/2 | |
| [203Pb]Pb-PSV359 + [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma | Phase 1/2 | |
| [203Pb]VMT-α-NET | Neuroendocrine Tumor Grade 2 | Phase 1 | |
| [212Pb] VMT-α-NET | Neuroendocrine Tumors | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competes in the nascent alpha-therapy space against companies like Actinium Pharmaceuticals (Ac-225) and Alpha Tau Medical, as well as large pharma entrants. Key differentiation is its proprietary Pb-212 platform and chemically matched Pb-203/Pb-212 theranostic pair, which may offer manufacturing and clinical workflow advantages.